Illumina wins new indication for TruSight Oncology in Europe

By staff writers

May 25, 2022 -- Illumina has received a new pan-cancer companion diagnostic (CDx) indication to the CE Mark for its TruSight Oncology Comprehensive (EU) test kit, which is currently being sold in Europe.

Launched in March initially in Europe, TruSight Oncology Comprehensive (EU) assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer, according to the company. The CDx pan-cancer indication will enable identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions including NTRK1, NTRK2, or NTRK3, and who may benefit from targeted therapy with Bayer's Vitravki (larotrectinib) drug.

The CDx claim was developed in partnership with Bayer, Illumina said.

Illumina to collaborate with Allegheny Health
Illumina plans to collaborate with Allegheny Health Network on a study regarding the impact on medical care of in-house genomic profiling for cancer patients.
Illumina sees revenue increases for Q1 as net income slips
Strong growth across multiple business units helped DNA sequencing developer Illumina report revenue increases for the first quarter of fiscal 2022 (end-April...
Illumina brings whole-genome sequencing to German hospital
Illumina has signed an agreement with Hannover Medical School in Germany to assess the use of rapid whole-genome sequencing (rWGS) in critically ill children...
Illumina hits Guardant with lawsuit over trade secrets
Illumina has hit Guardant Health with a lawsuit alleging Guardant and its founders Helmy Eltoukhy and AmirAli Talasaz misappropriated Illumina's trade...
Illumina releases in vitro cancer profiling test
Illumina has launched TruSight Oncology Comprehensive, a test that examines tumor genes and biomarkers to define the specific molecular profile of a patient's...

Copyright © 2022

Last Updated mp 5/25/2022 6:50:46 AM